Business Context and Reporting Period
Shuttle Pharmaceuticals Holdings, Inc. (SHPH), a Delaware corporation and emerging growth company, filed this Form 8-K on June 25, 2025, reporting events occurring on June 20 and June 24, 2025. The filing details a private placement transaction and related agreements.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of equity securities.
- Securities Issued: 21,924 shares of common stock and 1,158,953 pre-funded warrants.
- Pricing: $3.60 per share of common stock; $3.599 per pre-funded warrant.
- Warrant Terms: Immediately exercisable at $0.001; subject to a 4.99% beneficial ownership limitation.
- Placement Agent: WestPark Capital, Inc. received a fee of 4% of gross proceeds plus expense reimbursement.
- Liquidity and Debt: The filing does not provide specific values for total cash flow, existing debt, or liquidity ratios outside of the proceeds from this specific transaction.
Material Changes and Agreements
The primary material change is the entry into a Securities Purchase Agreement and a Registration Rights Agreement. Key provisions include:
- Registration Rights: The Company must file a resale registration statement within 10 days of closing (June 24, 2025) and have it declared effective within 90 days (or 120 days if reviewed by the SEC).
- Liquidated Damages: The Company is obligated to pay damages if it fails to meet the registration filing or effectiveness deadlines.
- Lock-Up Period: The Company and its directors/officers are restricted from issuing or selling additional equity for a period commencing at closing until the later of 60 days post-closing or 30 days after the registration statement becomes effective (capped at 120 days post-closing).
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of the financing. The filing highlights the following risks and contingencies:
- Regulatory Risk: Failure to timely file or have declared effective the resale registration statement triggers liquidated damages.
- Dilution Risk: The issuance of pre-funded warrants and common stock increases the share count, subject to the 4.99% beneficial ownership cap on warrant exercise.
- Market Conditions: The transaction was executed under Section 4(a)(2) of the Securities Act, indicating a private offering exempt from public registration.
Investor Verification Checklist
- Verify the exact gross proceeds calculated from the 21,924 shares and 1,158,953 warrants at the stated prices.
- Confirm the filing date and effectiveness status of the resale registration statement required within 10 days of June 24, 2025.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific liquidated damages formulas.
- Check the Company's updated capitalization table to assess the dilution impact of the new shares and warrants.
- Monitor the press releases filed as Exhibits 99.1 and 99.2 for additional context on the use of proceeds.